When Chemo Fails, This Rx May Help


Breast cancer patients and their doctors may now have a new tool in their toolbox.

A new study from Japan found that capecitabine (brand name Xeloda) may increase the rate of disease-free survival in women with HER2-negative breast cancer that was not successfully eliminated by presurgery chemotherapy.

“These [results] show that after two years of follow-up, disease-free survival was significantly improved by the addition of capecitabine to standard therapy,” said lead study author Masakazu Toi, MD, PhD, a professor at Kyoto University Hospital in Japan and founder of the Japan Breast Cancer Research Group, in a press release. “These data are exciting, because the side effects of the treatment were manageable and the benefit of capecitabine treatment was clear.”

Nguồn: https://inkstitch.net

Xem thêm bài viết khác: https://inkstitch.net/suc-khoe

Article Tags:
Article Categories:
Sức Khỏe

Leave a Reply

Your email address will not be published. Required fields are marked *